Results 111 to 120 of about 438,950 (335)

Compound Mutations in the Abl1 Kinase Cause Inhibitor Resistance by Shifting DFG Flip Mechanisms and Relative State Populations [PDF]

arXiv
The intrinsic dynamics of most proteins are central to their function. Protein tyrosine kinases such as Abl1 undergo significant conformational changes that modulate their activity in response to different stimuli. These conformational changes constitute a conserved mechanism for self-regulation that dramatically impacts kinases' affinities for ...
arxiv  

Characterization of the norepinephrine-activation of adenylate cyclase suggests a role in memory affirmation pathways. Overexposure to epinephrine inactivates adenylate-cyclase,a causal pathway for stress-pathologies [PDF]

BioSystems 100 (2010) p. 87-93, 2010
Incubation with noradrenaline (norepinephrine) of isolated membranes of rat's brain corpus striatum and cortex, showed that ionic-magnesium (Mg2+) is required for the neurotransmitter activatory response of Adenylate Cyclase [ATP pyrophosphate-lyase (cyclizing), (EC 4.6.1.1)], AC.An Mg2+-dependent response to the activatory effects of adrenaline, and ...
arxiv  

Chiral Engineered Biomaterials: New Frontiers in Cellular Fate Regulation for Regenerative Medicine

Advanced Functional Materials, EarlyView.
Chiral engineered biomaterials can selectively influence cell behaviors in regenerative medicine. This review covers chiral engineered biomaterials in terms of their fabrication methods, cellular response mechanisms, and applications in directing stem cell differentiation and tissue function.
Yuwen Wang, Xin Zhang, Denghui Xie, Chunying Chen, Zhifeng Huang, Zhong Alan Li   +5 more
wiley   +1 more source

Sustained Release of Proteins Using Region‐Specific Tunable Degradability in Hydrogels through 3D Photopatterning and Complimentary Labile Bond Chemistry

Advanced Functional Materials, EarlyView.
A series of ultraviolet‐ and near‐infrared radiation sensitive photoactivatable hydrogels are developed that can be controlled spatiotemporally down to µm precisions using one‐ and two‐photon uncaging. The latent hydroxylamine‐, hydrazine‐, and amine uncaged moieties are used to photopattern a series of diverse proteins displaying complimentary ...
Tove Kivijärvi, Carmine P. Cerrato, Taha Behroozi Kohlan, Paul O’Callaghan, Johan Kreuger, Marie Arsenian‐Henriksson, Anna Finne‐Wistrand   +6 more
wiley   +1 more source

Insulin-like growth factor I in cultured rat astrocytes: expression of the gene, and receptor tyrosine kinase. [PDF]

, 1987
Robert Ballotti, Finn Cilius Nielsen, Nigel P. Pringle, Aline Kowalski, William D. Richardson, Ellen Van Obberghen‐Schilling, Steen Gammeltoft   +6 more
openalex   +1 more source

Biomimetic Co‐delivery of Lenvatinib and FePt Nanoparticles for Enhanced Ferroptosis/Apoptosis Treatment of Hepatocellular Carcinoma

Advanced Healthcare Materials, EarlyView.
This study introduces a novel HCC treatment using poly lactic‐co‐glycolic acid (PLGA) nanoparticles encased in HCC cell membranes to co‐deliver Lenvatinib and FePt nanoparticles. This approach improves treatment efficacy by enhancing ferroptosis and apoptosis.
Feichao Xuan, Xingyang Zhao, Weiran Pang, Zirong Li, Xiangyi Yin, Weizhong Xie, Xiaojun Zeng, Liming Nie, Junying Yang, Shiying Li, Puxiang Lai, Chihua Fang   +11 more
wiley   +1 more source

Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses

American Journal of Hematology, Volume 98, Issue 1, Page 131-139, January 2023., 2023
Abstract Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk of severe COVID‐19. Patients and healthy controls (HC; N = 13) received two doses of BNT162b2: follicular lymphoma (FL; N = 35) who were treatment naïve (TN; N = 11) or received immunochemotherapy (ICT; N = 23) and Waldenström's macroglobulinemia
Brendan Beaton, Sarah C. Sasson, Katherine Rankin, Juliette Raedemaeker, Alexander Wong, Priyanka Hastak, Chansavath Phetsouphanh, Andrew Warden, Vera Klemm, C. Mee Ling Munier, Alexandra Carey Hoppe, Fiona Tea, Aleha Pillay, Alberto Ospina Stella, Anupriya Aggarwal, Orly Lavee, Ian D. Caterson, Stuart Turville, Anthony D. Kelleher, Fabienne Brilot, Judith Trotman   +20 more
wiley   +1 more source

Short‐Chain Fatty Acids Modulate Anti‐ROR1 CAR T‐Cell Function and Exhaustion in an Intestinal Adenocarcinoma‐on‐Chip Model

Advanced Healthcare Materials, EarlyView.
Short‐chain fatty acids modulate anti‐ROR1 chimeric antigen receptor (CAR) T‐cell function in an intestinal adenocarcinoma‐on‐chip model. Butyrate and propionate reduce cytotoxicity, cytokine release, and infiltration by inducing a regulatory T‐cell phenotype and T‐cell exhaustion via histone deacetylase inhibition.
Valentin D. Wegner, Adrian Feile, Miriam Alb, Michael Hudecek, Philip Hewitt, Alexander S. Mosig   +5 more
wiley   +1 more source

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

American Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Péter Reményi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kröger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha, on behalf of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +25 more
wiley   +1 more source

Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML

Clinical Medicine Insights: Oncology, 2011
The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase.
Marie P. Shieh, Masato Mitsuhashi, Michael Lilly   +2 more
doaj   +1 more source